中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

84 records (took 0.016 seconds)

    Treatment of fatigue, head injury and stroke
    51.
    发明授权
    Treatment of fatigue, head injury and stroke 失效
    疲劳，头部损伤和中风的治疗

    公开(公告)号：US06441038B1

    公开(公告)日：2002-08-27

    申请号：US09686629

    申请日：2000-10-12

    Applicant: Cari Loder ,  David F. Horrobin

    Inventor： Cari Loder ,  David F. Horrobin

    IPC: A61K31195

    CPC classification number: A61K31/55 ,  A61K45/06 ,  A61K2300/00

    Abstract: A method of treatment of disorders of neurological origin and drug formulations for use in the method are disclosed. These conditions comprise fatigue and associated syndromes of pain, weakness and depressed mood which are associated with chronic fatigue syndrome, brain injury and stroke, stress, fibromyalgia, and irritable bowel syndrome. The treatment comprises administering to a patient in need thereof a selective inhibitor of noradrenaline reuptake combined with either phenylalanine or tyrosine in the same dosage form or the same pack.# The noradrenergic drug may be selected from lofepramine, desipramine or reboxetine. The selective inhibitor may be a combined inhibitor of both noradrenaline and serotonin reuptake such as venlafaxine, duloxetine or milnacipran, or an inhibitor of both noradrenaline and dopamine reuptake such as bupropion.

    Abstract translation: 公开了一种治疗神经源性疾病的方法和用于该方法的药物制剂。 这些病症包括与慢性疲劳综合征，脑损伤和中风，压力，纤维肌痛和肠易激综合征相关的疲劳和相关的疼痛，虚弱和抑郁情绪综合征。 该治疗包括向有需要的患者施用去甲肾上腺素再摄取的选择性抑制剂与相同剂型或相同包装中的苯丙氨酸或酪氨酸组合。＃去甲肾上腺素能药可以选自洛哌匹灵，地昔帕明或瑞波西汀。 选择性抑制剂可以是去甲肾上腺素和5-羟色胺再摄取的组合抑制剂，如文拉法辛，度洛西汀或米那普仑，或去甲肾上腺素和多巴胺再摄入如安非他酮的抑制剂。

    Fatty acid treatment
    52.
    发明授权
    Fatty acid treatment 失效
    脂肪酸处理

    公开(公告)号：US5888541A

    公开(公告)日：1999-03-30

    申请号：US784105

    申请日：1997-01-15

    Applicant: David F. Horrobin ,  Brenda E. Reynolds

    Inventor： David F. Horrobin ,  Brenda E. Reynolds

    IPC: A61K31/201 ,  A61K35/78 ,  A61K9/20

    CPC classification number: A61K31/201

    Abstract: Increase gut calcium absorption in humans or animals by the administration of GLA, DGLA or LA as such or in salt or other pharmacologically acceptable form, optionally in association with EPA, DHA or other EFA in similar forms, specifically useful in the treatment of osteoporosis.

    Abstract translation: 通过施用GLA，DGLA或LA本身或以盐或其他药理学上可接受的形式，任选地与EPA，DHA或其他类似形式的EFA相关联地增加对人或动物的肠吸收钙吸收，特别可用于治疗骨质疏松症。

    Stabilization of polyunsaturates
    53.
    发明授权
    Stabilization of polyunsaturates 失效
    多不饱和化合物的稳定化

    公开(公告)号：US5871757A

    公开(公告)日：1999-02-16

    申请号：US628692

    申请日：1996-10-16

    Applicant: John B. Cloughley ,  David F Horrobin

    Inventor： John B. Cloughley ,  David F Horrobin

    IPC: A61K47/44 ,  A23D9/06 ,  A61K36/67 ,  C11B5/00 ,  C11B9/02 ,  A61K7/48 ,  A61K35/78

    CPC classification number: C11B5/0085 ,  A23D9/06

    Abstract: Polyunsaturated oils such as triply or higher ethylenically unsaturated organic materials are stabilized against ambient temperature atmospheric oxidation by the addition of an essential oil such as thyme oil, oregano oil, pepper oil or clove oil.

    Abstract translation: PCT No.PCT / GB94 / 02277 Sec。 371日期1996年10月16日第 102（e）日期1996年10月16日PCT 1994年10月18日PCT公布。 WO95 / 11289 PCT出版物 日期1995年04月27日多不饱和油如三元或更高的烯键式不饱和有机材料通过加入精油如百里香油，牛至油，胡椒油或丁香油，稳定于环境温度大气氧化。

    Treatment of internal radiation damage
    56.
    发明授权
    Treatment of internal radiation damage 失效
    治疗内部辐射损伤

    公开(公告)号：US5583159A

    公开(公告)日：1996-12-10

    申请号：US408135

    申请日：1995-03-21

    Applicant: David F. Horrobin ,  Catherine A. Scott

    Inventor： David F. Horrobin ,  Catherine A. Scott

    IPC: A61K31/20 ,  A61K31/202 ,  A61P25/00 ,  A61P43/00

    CPC classification number: A61K31/202 ,  A61K31/20

    Abstract: Damage to internal tissues, and particularly to the central nervous system as a consequence of exposure to ionizing radiation is prevented or treated by administration of GLA and/or DGLA. Medicaments containing GLA and/or DGLA for such treatment or prevention may also further comprise EPA and/or DHA.

    Abstract translation: 通过施用GLA和/或DGLA来防止或治疗由于暴露于电离辐射而对内部组织，特别是对中枢神经系统的损伤。 含有GLA和/或DGLA用于治疗或预防的药物还可以进一步包含EPA和/或DHA。

    Method for the safe administration of fatty acid
    57.
    发明授权
    Method for the safe administration of fatty acid 失效
    脂肪酸安全施用方法

    公开(公告)号：US5508307A

    公开(公告)日：1996-04-16

    申请号：US378708

    申请日：1995-01-26

    Applicant: David F. Horrobin ,  Catherine A. Scott

    Inventor： David F. Horrobin ,  Catherine A. Scott

    IPC: A61K31/20 ,  A61K20060101 ,  A61K9/08 ,  A61K31/201 ,  A61K31/202 ,  A61K31/203 ,  A61K33/00

    CPC classification number: A61K31/20

    Abstract: Method of safe intravenous administration of fatty acid(s), and in particular the n-6 and n-3 series essential fatty acids and conjugated fatty acids, whereby the fatty acid(s) or a proportion thereof are administered in the form of lithium salts, and whereby the plasma lithium levels are regularly monitored to avoid haemolysis, preferably keeping the lithium level no higher than 0.7 millimolar in the long term and preferably also no higher than 0.4-0.5 millimolar in the first 24-48 hours or, where only a proportion of the fatty acids are administered as lithium salts, a corresponding proportion of said levels.

    Abstract translation: 脂肪酸的安全静脉内给药方法，特别是n-6和n-3系列必需脂肪酸和共轭脂肪酸，其中脂肪酸或其一部分以锂的形式施用 盐，并且由此定期监测血浆锂水平以避免溶血，优选在长期内保持锂水平不高于0.7毫摩尔，优选在第一24-48小时内不超过0.4-0.5毫摩尔，或者仅在 一部分脂肪酸以锂盐的形式施用，相应比例的水平。

    Method of increasing the total fat content of milk
    58.
    发明授权
    Method of increasing the total fat content of milk 失效
    增加牛奶总脂肪含量的方法

    公开(公告)号：US5264217A

    公开(公告)日：1993-11-23

    申请号：US959472

    申请日：1992-10-09

    Applicant: David F. Horrobin

    Inventor： David F. Horrobin

    IPC: A61K31/20

    CPC classification number: A61K31/20 ,  Y10S514/922

    Abstract: Methods for increasing the total fat and therefore energy content of mammalian and particularly human milk, the essential fatty acid content of that milk and the flow of that milk during lactation, or for preventing or reducing the normal decrease in milk fat content that occurs during prolonged lactation, by administering gamma linolenic acid, dihomo-gamma-linolenic acid or their mixture, alone or a physiologically acceptable diluent or carrier, in a form administrable to the lactating female.

    Abstract translation: 增加哺乳动物和特别是人乳的总脂肪，因此能量含量的方法，该乳的必需脂肪酸含量和哺乳期间该奶的流动，或用于预防或减少在长时间内发生的乳脂含量的正常降低 通过以可施用于哺乳期雌性的形式单独或单独或生理上可接受的稀释剂或载体施用γ-亚麻酸，二亚非 - γ-亚麻酸或其混合物。

Patent Agency Ranking